Minireviews
Copyright ©The Author(s) 2021.
World J Gastroenterol. Nov 21, 2021; 27(43): 7497-7508
Published online Nov 21, 2021. doi: 10.3748/wjg.v27.i43.7497
Table 3 Treatment indications for patients in the hepatitis B e-antigen-negative immune-inactive phase

Monitor criteria
Consideration for anti-viral therapy
EASL[15]Normal ALT (< 40 IU/L) and HBV DNA (< 2000 IU/mL) levels. Monitor ALT and HBV DNA levels (< 2000 IU/mL)every 6-12 mo, (≥ 2000 IU/mL)every 3-6 moAge > 30 yr, family history of HCC or cirrhosis and extrahepatic manifestations
APASL[16] Normal ALT (< 40 IU/L) and HBV DNA (< 2000 IU/mL) levels. Monitor ALT and HBV DNA levels every 3-6 moAge > 35 yr, liver biopsy showing F2 or A2, significant fibrosis by non-invasive tests, stiffness ≥ 8 kPa, persistently elevated ALT, family history of HCC/cirrhosis
AASLD[17]Normal ALT [< 35 IU/L (male), < 25 IU/L (female)] and HBV DNA (< 2000 IU/mL) levels. Monitor ALT and HBV DNA levels every 3 mo for 1 yr, then every 6 moLiver biopsy or non-invasive test shows ≥ F2 or F3, persistently elevated ALT level; exclude other causes, especially age > 40 yr
JSG[18]Normal ALT level (≤ 30 IU/L) and HBV DNA (< 2000 IU/mL) levelsConsider liver biopsy or non-invasive test if age > 40 yr, high HBV DNA or platelet counts < 15 × 104/uL, family history of HCC